同步转移性肾细胞癌接受舒尼替尼治疗患者中立即与延迟减瘤性肾切除术的比较:SURTIME随机临床试验
SURTIME随机临床试验比较了立即减瘤性肾切除术序贯舒尼替尼与先行3周期舒尼替尼后无进展再行减瘤性肾切除术治疗同步转移性透明细胞肾细胞癌的疗效。研究因入组缓慢提前关闭,共纳入99例患者。28周无进展率两组无显著差异,但延迟组总生存期更长,且更多患者接受了舒尼替尼治疗。
要点
- 延迟减瘤性肾切除术组28周无进展率为43%,立即手术组为42%,差异无统计学意义。
- 延迟组中位总生存期为32.4个月,立即组为15.0个月,风险比为0.57。
- 延迟组49例中48例(98%)接受了舒尼替尼,立即组50例中40例(80%)接受了舒尼替尼。
核心结论
- 延迟减瘤性肾切除术未改善28周无进展率。
- 采用延迟策略时,更多患者接受了舒尼替尼且总生存结果更高。
- 舒尼替尼术前治疗可能识别出对全身治疗存在内在耐药的患者。
研究设计与样本
- 随机临床试验,2010年7月14日开始,2016年3月24日结束,中位随访3.3年,本报告临床截止日期为2017年5月5日。
- 研究对象为透明细胞亚型转移性肾细胞癌、原发肿瘤可切除且手术风险因素不超过3个的患者。
- 干预措施为立即减瘤性肾切除术序贯舒尼替尼治疗对比先行3周期舒尼替尼治疗,无进展者再行减瘤性肾切除术,术后继续舒尼替尼治疗。
- 主要终点为无进展生存期,所需样本量为458例;因入组缓慢,独立数据监测委员会同意改为报告意向性治疗28周无进展率。
- 研究因入组缓慢提前关闭,共纳入99例患者(80例男性,19例女性;平均[标准差]年龄60[8.5]岁)。
主要发现
- 28周无进展率在立即减瘤性肾切除术组(n=50)为42%,在延迟减瘤性肾切除术组(n=49)为43%(P=0.61)。
- 意向性治疗总生存风险比(延迟组 vs 立即组)为0.57(95%CI,0.34-0.95;P=0.03)。
- 中位总生存期在延迟组为32.4个月(95%CI,14.5-65.3个月),在立即组为15.0个月(95%CI,9.3-29.5个月)。
- 延迟组49例中48例(98%;95%CI,89%-100%)接受了舒尼替尼,立即组50例中40例(80%;95%CI,67%-89%)接受了舒尼替尼。
- 在延迟组中,计划减瘤性肾切除术前的全身性进展导致14例患者(29%;95%CI,18%-43%)按方案建议不予肾切除术。
临床怎么用
- 作者认为,舒尼替尼术前治疗可能识别出对全身治疗存在内在耐药的患者,从而在计划减瘤性肾切除术之前指导治疗决策。
- 作者指出,该证据补充了近期随机临床试验的数据,有助于为需要舒尼替尼治疗的原发性透明细胞转移性肾细胞癌患者的治疗决策提供信息。
局限性
- 研究因入组缓慢提前关闭,实际样本量为99例,低于原计划所需458例。
- 主要终点因入组缓慢由无进展生存期改为意向性治疗28周无进展率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown. OBJECTIVE: To examine whether a period of sunitinib therapy before CN improves outcome compared with immediate CN followed by sunitinib. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial began as a phase 3 trial on July 14, 2010, and continued until March 24, 2016, with a median follow-up of 3.3 years and a clinical cutoff date for this report of May 5, 2017. Patients with mRCC of clear cell subtype, resectable primary tumor, and 3 or fewer surgical risk factors were studied. INTERVENTIONS: Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy. MAIN OUTCOMES AND MEASURES: Progression-free survival was the primary end point, which needed a sample size of 458 patients. Because of poor accrual, the independent data monitoring committee endorsed reporting the intention-to-treat 28-week progression-free rate (PFR) instead. Overall survival (OS), adverse events, and postoperative progression were secondary end points. RESULTS: The study closed after 5.7 years with 99 patients (80 men and 19 women; mean [SD] age, 60 [8.5] years). The 28-week PFR was 42% in the immediate CN arm (n = 50) and 43% in the deferred CN arm (n = 49) (P = .61). The intention-to-treat OS hazard ratio of deferred vs immediate CN was 0.57 (95% CI, 0.34-0.95; P = .03), with a median OS of 32.4 months (95% CI, 14.5-65.3 months) in the deferred CN arm and 15.0 months (95% CI, 9.3-29.5 months) in the immediate CN arm. In the deferred CN arm, 48 of 49 patients (98%; 95% CI, 89%-100%) received sunitinib vs 40 of 50 (80%; 95% CI, 67%-89%) in the immediate arm. Systemic progression before planned CN in the deferred CN arm resulted in a per-protocol recommendation against nephrectomy in 14 patients (29%; 95% CI, 18%-43%). CONCLUSIONS AND RELEVANCE: Deferred CN did not improve the 28-week PFR. With the deferred approach, more patients received sunitinib and OS results were higher. Pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN. This evidence complements recent data from randomized clinical trials to inform treatment decisions in patients with primary clear cell mRCC requiring sunitinib. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01099423.
引用
- Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 30543350. doi:10.1001/jamaoncol.2018.5543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。